文献速递免疫规划

18月龄儿童联合接种Sabin株脊髓灰质炎灭活疫苗、无细胞百白破疫苗和甲肝减毒活疫苗的免疫原性与安全性:中国多中心随机对照非劣效试验

Immunogenicity and safety of co-administration of sabin-strain-based inactivated poliovirus vaccine, diphtheria-tetanus-acellular pertussis vaccine, and live attenuated hepatitis A vaccine in 18-month-old children: A multicenter randomized controlled non-inferiority trial in China.
PubMed 文献 · Vaccine · 2025-10-27

在中国18月龄健康儿童中开展多中心、随机、开放标签、非劣效IV期试验,593名受试者按1:1:1:1随机分组,比较sIPV、DTaP和HepA-L联合接种与分别接种的免疫原性和安全性。联合接种组所有抗原的免疫原性均非劣效于分别接种组,不良事件率总体相当,但联合接种组总体不良反应发生率(11.49%)高于HepA-L单独接种组(4.70%,P=0.032)。结论认为同时接种sIPV+DTaP+HepA-L免疫原性非劣效且安全性可接受。

要点

  • 联合接种组与分别接种组所有抗原的免疫原性均达到非劣效标准。
  • 联合接种组总体不良反应发生率11.49%,高于HepA-L单独接种组的4.70%(P=0.032)。
  • 大多数不良反应为1-2级,3级事件罕见(各组≤1.35%),未报告疫苗相关严重不良事件。

核心结论

  • 同时接种sIPV+DTaP+HepA-L免疫原性非劣效且安全性可接受,支持其潜在整合以优化免疫规划。

研究设计与样本

  • 多中心、随机、开放标签、非劣效IV期试验,扩展自先前研究(NCT04053010),纳入18月龄健康中国儿童。
  • 计划入组600名,实际入组并随机593名(1:1:1:1),2020年11月至2021年1月间分组:第1组(n=148)同时接种sIPV、DTaP和HepA-L;第2/3/4组(n=148/148/149)分别单独接种sIPV、DTaP或HepA-L作为对照。
  • 免疫原性非劣效性通过调整几何均值比(联合接种组 vs 分别接种组,按抗原)评估,预设95%CI下限界值为0.67。
  • 基线及接种后30天检测抗体滴度:脊髓灰质炎中和抗体(CPE法;倒数ND50滴度)、DTaP抗体(ELISA;IU/mL)、HepA-L IgG(电化学发光免疫分析法;IU/L)。
  • 接种后6个月安全性监测,记录任何不良事件或严重不良事件。

主要发现

  • 联合接种组与分别接种组抗体几何均值:脊髓灰质炎I型1271.21 vs 1255.79,II型1915.91 vs 2076.62,III型2306.41 vs 2416.62。
  • 联合接种组与分别接种组抗体几何均值:白喉3.52 vs 3.31 IU/mL,百日咳类毒素53.87 vs 64.11 IU/mL,丝状血凝素36.02 vs 35.73 IU/mL,破伤风9.23 vs 9.08 IU/mL,甲肝513.24 vs 439.25 IU/L。
  • 接种后30天内,联合接种组总体不良反应发生率为11.49%,高于第4组(HepA-L单独接种)的4.70%(P=0.032),但与第2组(9.46%)和第3组(6.08%)相当。
  • 各组征集性局部反应发生率相似,以硬结和红肿最常见;发热是最主要的全身反应。
  • 大多数不良反应为1-2级,3级事件罕见(各组≤1.35%),未报告疫苗相关严重不良事件。

关键数值与推荐

  • 免疫原性非劣效性预设界值为95%CI下限0.67。
  • 联合接种组与分别接种组所有抗原的免疫原性均非劣效。
  • 联合接种组总体不良反应发生率11.49% vs 第4组4.70%(P=0.032)。
  • 3级不良事件各组≤1.35%。

临床怎么用

  • 原文结论支持同时接种sIPV+DTaP+HepA-L的潜在整合以优化免疫规划。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Frequent healthcare visits increase children's risk of cross-infection. In both routine and emergency settings settings, co-administering vaccines or using combination vaccines can improve coverage, compliance, and timeliness. Vaccination is among the most cost-effective public health measures, with high coverage being critical for success, minimal immune interference, and improved programmatic efficiency. METHODS: This multicenter, randomized, open-label, non-inferiority phase IV trial extended a prior study (NCT04053010) to evaluate the immunogenicity and safety of co-administering sIPV, DTaP, and HepA-L in healthy Chinese children aged 18 months. Among 600 planned participants, 593 were enrolled and randomized (1:1:1:1) between November 2020 and January 2021: Group 1 (n = 148) received sIPV, DTaP, and HepA-L concomitantly; Groups 2/3/4 (n = 148/148/149) received sIPV, DTaP, or HepA-L separately as comparator controls. Immunogenicity non-inferiority was assessed via adjusted geometric mean ratios (co-ad group vs. sep-ad group per antigen) for poliovirus types I/II/III, DTaP components (DT, TT, PT, FHA), and HepA-L, with a prespecified margin of 0.67 for the 95 % CI lower bound. Antibody titers were assessed at baseline and 30 days post-vaccination: Poliovirus neutralizing antibodies (CPE method; reciprocal ND50 titer), DTaP antibodies (ELISA; IU/mL), HepA-L IgG (electrochemiluminescence immunoassay; IU/L). Safety was monitored for 6 months after vaccination to record any adverse events or serious adverse events. RESULTS: Co-administration demonstrated non-inferior immunogenicity compared to separate administration for all antigens: polio types I (1271.21 vs. 1255.79), II (1915.91 vs. 2076.62), III (2306.41 vs. 2416.62); diphtheria (3.52 vs 3.31 IU/mL), pertussis toxoid (53.87 vs. 64.11 IU/mL); filamentous hemagglutinin (36.02 vs. 35.73 IU/mL), tetanus (9.23 vs 9.08 IU/mL), and hepatitis A (513.24 vs. 439.25 IU/L). Adverse event rates were comparable. Within 30 days post-vaccination, the overall adverse reaction (AR) incidence was higher in the co-administration group (11.49 %) than in Group 4 (4.70 %; P = 0.032) but was comparable to that in Group 2 (9.46 %) and Group 3 (6.08 %). Solicited local reactions occurred at similar rates across groups, with induration and redness being the most frequent. Similarly, fever was the predominant systemic reaction. Most ARs were Grade 1-2 in severity; Grade 3 events were rare (≤1.35 % across groups). No vaccine-related serious adverse events were reported. CONCLUSION: Simultaneous sIPV+DTaP+HepA-L administration is immunologically non-inferior and exhibits an acceptable safety profile, supporting its potential integration to optimize immunization programs. CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/study/NCT04636827?cond=NCT04636827&rank=1-ID:NCT04636827.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Liu X, Han S, Wang H, et al. Immunogenicity and safety of co-administration of sabin-strain-based inactivated poliovirus vaccine, diphtheria-tetanus-acellular pertussis vaccine, and live attenuated hepatitis A vaccine in 18-month-old children: A multicenter randomized controlled non-inferiority trial in China. Vaccine. 2025. PMID: 41151164. doi:10.1016/j.vaccine.2025.127891

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。